For example, ATL-I mitigates liver damage by inhibiting TLR4/mitogen-activated protein kinase (MAPK)/NF-κB signalling [40], increasing the chemosensitivity of cancer cells to paclitaxel through the regulation of TLR4/MyD88 signalling [41], and decreasing breast cancer progression via the inhibition of TLR4/NF-κB signalling [14]. Here, MYD88 is linked to breast carcinoma.